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ABSTRACT
Significant variations in the frequency of single nucleotide polymorphisms (SNPs) of human leukocyte antigen among Taiwan’s
aboriginal tribes and high homogeneity within each tribe have been reported. To identify variations in genetic polymorphisms
of drug-metabolizing enzyme in seven of Taiwan’s ethnic groups, the SNPs of N-acetyl transferase 2, a conjugation enzyme in
phase II metabolism, were investigated. Methods: Three SNPs of NAT2, NAT2*5, NAT2*6, and NAT2*7, were determined by the
TaqMan method and subsequently confirmed by polymerase chain reaction-restriction fragment length polymorphism (PCRRFLP). Our results showed statistically significant variations in the frequency of NAT2 genotype categories according to the 3 SNPs
of NAT2 within 7 Taiwanese ethnic groups (Chi-square = 32.08, p<0.05). The distribution of the frequency of the slow acetylator
genotype ranged from 32.0% in the Hakka population to 75.5% in the Paiwan population. A lack of NAT2*5 SNP alleles was found
in the Atayal population, while a NAT2*5 allele frequency of 31.6% was observed in the Paiwan group. The frequencies of allele
NAT2*6 and NAT2*7 in the investigated ethnic groups ranged from 11.2-37.0% and 17.0-53%, respectively. Our results also showed
the considerable variations in drug-metabolizing enzyme NAT2 genotypes among Taiwan’s aboriginal and general population. The
variation in the genetic polymorphisms of drug-metabolizing enzyme in Taiwan’s groups is worthy of further study to understand
different therapeutic and adverse drug responses in ethnic groups.
Key words: N-acetyltransferase 2, aboriginal, single nucleotide polylmorphism, Taiwan

INTRODUCTION
Arylamine N-acetyltransferase 2 (NAT2), a xenobiotic metabolizing enzyme in O- or N-acetylation of
aromatic and heterocyclic amines, has been demonstrated
to be associated with drug response and cancer development (1-6). Patients with low NAT2 activity have a higher
risk of developing severe skin reactions and hepatitis
when treated with sulphonamide and isoniazid, respectively(4,5). In addition, some evidence suggests that
people with the slow acetylation genotype had the risk of
colorectal and breast cancers (2,6). Therefore, it may be
important to understand the functional NAT2 activity in
each individual to avoid excessive exposure to certain
drugs and environments.
The relationships between genotypes and phenotypes
* Author for correspondence. Tel: 886-2-23123456 ext. 88411;
Fax: 886-2-23919098; E-mail: ljshen@ntu.edu.tw

have been elucidated via recombinant human NAT2 alleles
with specific nucleotide substitutions in an Escherichia
coli expression system(7). A number of single nucleotide polymorphisms (SNPs) of NAT2 that influence NAT2
activity has been systematically classified and applied in
the human clinical studies (8,9). Reduced enzyme activity
is associated with some SNPs of NAT2, such as NAT2*5
(C341T, rs1801280), NAT2*6 (G590A, rs1799930), NAT2*7
(G857A, rs1799931), and NAT2*14 (G191A, rs1801279),
compared to the wild-type allele NAT2*4(7). NAT2 acetylation activity can be divided into 3 classes, namely rapid,
intermediate, or slow acetylation, when the genotypes
contain two alleles, one allele or none allele of NAT2*4,
respectively(9,10). Nevertheless, the first two categories
were combined as the rapid acetylation classification in
some reports. Because the NAT2*14 genotype is rare in
the Asian population(11,12), only 3 SNPs, NAT2*5, *6, and
*7, were examined in this study.
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The ethnic difference in the NAT2 polymorphism
has been observed in several studies (2,12-20). Various frequencies of slow acetylators have been reported
from 6.1%, 16.6-24.1%, 44.3%, and 55.0% in the Japanese, Taiwanese, North Indian, and Caucasian populations, respectively. Taiwan’s population is composed of
1.5% aboriginal people, 7.5% mainland Chinese from
China after War World II, and 91% Minnan and Hakka
from southeast coast of China since the 17th century(21).
Researchers often use Chinese as representatives of
Asian people and the Minnan/Hakka or so-called Han
people as subjects in clinical studies. However, genetic
variations in metabolizing enzymes among Taiwan’s
indigenous tribes and Minnan/Hakka were poorly investigated. On the other side, remarkable genetic variations
in human leukocyte antigen (HLA) between Taiwan
aborigines and Minnan/Hakka have been reported by
Lin et al.(22,23). Their results showed homogeneity in
each tribe and heterogeneity among the different tribes
with respect to HLA SNPs, due to long-term geographical isolation. Taiwan aborigines were divided into nine
ethnic groups according to their linguistic, cultural, and
geographical features. Different hypotheses regarding
the origin of Taiwan aboriginal ethnic groups have been
raised from the approaches of archaeology and linguistics (24,25). Until recently, genetic distances by mitochondria DNA polymorphisms were employed to investigate
the origin of Taiwan aboriginal populations from the
genetic viewpoint (26,27). Taiwan aboriginal populations
appeared closer to island Southern Asian populations,
e.g. Philippines, Indonesia, etc., than to the population
from mainland East Asia, e.g. Minnan/Hakka, SouthChina, North-China, etc., according to the results of
the principle component analysis (27). Furthermore, the
geographical feature was correspondent with the map of
genetic markers in Taiwanese aboriginal ethnic groups,
i.e., genetic distances revealed distinct clusters that were
composed of the southernmost populations (Paiwan,
Puyuma, and Rukai), Yami from the Orchid Island, and
the northern (Atayal, Saisiat), and central/east coast
populations (Tsou, Bunun, and Ami)(27). However, Ami
showed closer to the southern than to the central/east
coast populations by the other haplogroup frequencies (27).
Although mitochondrial DNA polymorphisms analysis
provided useful information to understand the origin of
Taiwan ethnic groups, the results remained inconsistent
with other research group (26).
Therefore, we hypothesized that the frequency of
NAT2 SNPs is varied among Taiwan ethnic groups, which
may contribute to the variant responses to the medications involving NAT2 metabolism. To test our hypothesis, the NAT2 genotype in Taiwan ethnic groups, 5
aboriginal groups and 2 general populations were included in this study. This is the first study to explore SNPs
distribution of the drug metabolizing enzyme, NAT2,
among Taiwan’s ethnic groups.

MATERIALS AND METHODS
I. Subjects
Human DNA samples were collected at Transfusion
Medicine Research Laboratory of the Mackay Memorial Hospital in Taipei, Taiwan(22). The recruited subjects
have signed the consents to participate in the study. The
research was also approved by the Institutional Review
Board, Mackay Memorial Hospital, Taipei, Taiwan,
under clinical trial number NCT00459251. The aboriginal groups were defined by the geographical area where
the aboriginal populations reside. In addition, only
those whose parents were from the same tribes and who
were unrelated to other participants as confirmed by the
tribal chiefs, were included in our study. Five aboriginal
tribes, Atayal (AT), Tsou (TS), Paiwan (PW), Ami (AM),
and Yami (YM), and general Taiwanese groups, Hakka
(HK) and Minna (MN), were included in this study. Five
aboriginal groups were selected in our study because of
their definite populations among the nine tribes with less
effect of admixture by other surrounding populations
and also representing different geographical areas. The
Atayl, Tsou, and Paiwan inhabit the north, middle, and
south of the central mountain area of Taiwan main island,
respectively. The Ami lives the plains of the east coast
surrounded by mountains and Pacific Ocean. The Yami
resides Orchid Island, located off the eastern coast of
the main island. If an aboriginal group spread in different areas, the participants were recruited from different
areas in order to represent of a specific ethnic population
in this study. Around 50 individual DNA samples from
each ethnic group were analyzed to elucidate the allele
frequency of NAT2 genotypes.
II. NAT2 Genotype Assay
TaqMan drug metabolism genotyping assays
(Applied Biosystems, Foster City, CA, USA), using endpoint fluorescence (ABI Prism 7900HT Sequence
Detection System Software version 2.2.1), were used for
high throughput determination of NAT2 genotype polymorphisms, NAT2*5, NAT2*6, NAT2*7.
Polymerase chain reaction-restriction fragment
length polymorphism (PCR-RFLP) was also performed
to confirm the results and identified the undetermined
samples from TaqMan drug metabolism genotyping assays (12). Briefly, the NAT2 gene was amplified by
PCR with primers of sequences, 5’-GGAACAAATTGGACTTGG-3’ and 5’-TCTAGCATGAATCACTCTGC3’ (Operon Biotechnologies, Cologne, Germany). PCR
mixture was composed of 1X Colorless Gotaq Reaction Buffer (Promega Corporation, Madison, WI, USA),
1 U Gotaq DNA polymerase, 100 ng DNA template, 0.2
pmol of each primer, 0.4 mM dNTPs and deionized water
in a final volume of 25 µL. PCR program settings were
preheating at 95°C for 5 min, 35 cycle of 95°C for 40s,
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62.5°C for 30s, 72°C for 90s, and then extension at 72°C
for 10 min. A 25-µL aliquot of PCR product was digested
with restriction enzymes KpnI (C341T), Taqα I (G590A),
or BamHI (G857A) for 16 h. The digested products were
resolved by electrophoresis in 2% agarose gel (AMRESCO AgaroseI TM ) at 100 V for 35 min.
Each individual sample was classified into 3 classes
(the rapid, intermediate, and slow NAT2 acetylation genotypes) when carrying two wild alleles (NAT2*4/*4), one
wild allele (NAT2*4/*5, NAT2*4/*6, and NAT2*4/*7), and
two mutant allele (NAT2*5/*5, NAT2*5/*6, NAT2*5/*7,
NAT2*6/*6, NAT2*6/*7, and NAT2*7/*7), respectively (9).
III. Statistical Analysis.
The statistical significance was evaluated by Chisquare test using the SPSS 11.5.0 (SPSS Inc. Chicago, IL,
USA) program. A value of p<0.05 was considered statistically significant.

RESULTS
I. NAT2*5 Allele
The allele frequency of SNP of NAT2*5 in studied
Taiwan ethnic groups varied from 0.0 to 31.6% (Table 1).
NAT2*5 SNP allele was not detected in the Atayal tribe. In
contrast, the high frequency, 31.6%, of NAT2*5 SNP was
observed in the Paiwan tribe. The percentages of wild
type, heterozygote, and homozygote of NAT2*5 populations were 42.9%, 51.0%, and 6.1%, respectively, in the
Paiwan population. The allele frequency of NAT2*5 in the
other groups ranged from 6.0 to 11.0%. Individuals homozygous for NAT2*5 were only identified in the Paiwan (3
persons) and Yami (1 person) populations.
II. NAT2*6 Allele
The allele frequency of SNP of NAT2*6 in investigated groups ranged from 11.2 to 37.0% (Table 1). The
higher distribution of NAT2*6, 37.0 and 33.0%, was
observed in the Ami and Tsou tribes, respectively. On

the other hand, lower frequencies of 15.0 and 11.2% were
observed in the Atayal and Paiwan populations, respectively. The distribution of NAT2*6 was similar in Yami,
Hakka, and Minnan groups.
III. NAT2*7 Allele
The allele frequency of NAT2*7 varied in the
Taiwanese ethnic groups (Table 1). The Paiwan and
Atayal populations had higher proportions, 41.8 and
53.0%, respectively, relative to other groups. 7 of 49 and
16 of 50 persons are NAT2*7 homozygous in the Paiwan
and Atayal tribes, respectively.
IV. NAT2 Genotypes Classification
The NAT2 phenotypes in the studied population
according to the genotype classification of NAT2*4, *5,
*6, and *7 are depicted in Table 2. The difference in the
three genotype categories (rapid, intermediate, and slow
acetylator) among each of 7 Taiwanese ethnic populations
was statistical significant by Chi-square test (Chi-square
= 32.08, DF=12, p < 0.05). Only 6.1% of the Paiwan population was classified as the rapid acetylation genotype,
NAT2*4/*4. However, the rapid acetylation genotype were
observed in 28% of the Hakka and Minnan populations.
Among the aboriginal groups, the frequency of rapid
acetylator varied from 6.1 to 20%. The low proportions
of intermediate acetylation genotypes, 18.4% and 28%,
represent in the Paiwan and Ami populations, respectively. The high proportion of intermediate acetylation
genotypes in the other groups ranging from 34 to 40%
was observed. Obviously, very high percentage of slow
acetylators (75.5%) were observed in the Paiwan population in our study with statistical significance comparing to other ethnic groups. Subsequently, 56%, 48%, and
43.8% of Ami, Atayal, and Yami tribes, respectively, were
reported as slow acetylators. Similar distributions of the
slow acetylation genotypes in Tsou, Hakka, and Minnan
tribes were observed. In addition, the distribution of the
combined NAT2 genotypes in each ethnic population did
not differ significantly, as derived from Hardy-Weinberg
equilibrium at significant level α = 10 -3(28).

Table 1. Frequency distribution of NAT2 genotypes in Taiwanese ethnic populations
Allele
frequency*

Groups

Ami

Atayal

Paiwan

Tsou

Yami

Hakka

Minnan

NAT2*4

30/100 (30)

32/100 (32)

15/98 (15.3)

43/100 (43)

36/96 (37.5)

48/100 (48)

45/100 (45)

NAT2*5

11/100 (11)

0/100 (0)

31/98 (31.6)

7/100 (7)

9/96 (9.4)

6/100 (6)

6/100 (6)

NAT2*6

37/100 (37)

15/100 (15)

11/98 (11.2)

33/100 (33)

19/96 (19.8)

21/100 (21)

27/100 (27)

NAT2*7

22/100 (22)

53/100 (53)

41/98 (41.8)

17/100 (17)

32/96 (33.3)

25/100 (25)

22/100 (22)

Allele frequency* was calculated according to a formula: (2nx/x + nx/-)/2n, where nx/x is the number of individuals homozygous for X and
nx/- heterozygous for X. X stands for each single nucleotide polymorphism of NAT2.
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Table 2. Distribution of NAT2 phenotypes according to genotypes in Taiwanese ethnic populations
Groups
Genotypes

Ami
n/total (%)

Atayal
n/total (%)

Paiwan
n/total (%)

Tsou
n/total (%)

Yami
n/total (%)

Hakka
n/total (%)

Minnan
n/total (%)

NAT2 rapid acetylator
NAT2*4/*4

8/ 50 (16)

6/ 50 (12)

3/ 49 (6.1)

10/ 50 (20)

9/ 48 (18.8)

14/ 50 (28)

14/ 50 (28)

Total

8/ 50 (16)

6/ 50 (12)

3/ 49 (6.1)

10/ 50 (20)

9/ 48 (18.8)

14/ 50 (28)

14/ 50 (28)

NAT2 intermediate acetylator
NAT2*4/*5

4/ 50 (8)

0/ 50 (0)

4/ 49 (8.2)

4/ 50 (8)

0/ 48 (0)

5/ 50 (10)

1/ 50 (2)

NAT2*4/*6

10/ 50 (20)

5/ 50 (10)

2/ 49 (4.1)

13/ 50 (26)

6/ 48 (12.5)

9/ 50 (18)

11/ 50 (22)

NAT2*4/*7

0/ 50 (0)

15/ 50 (30)

3/ 49 (6.1)

6/ 50 (12)

12/ 48 (25)

6/ 50 (12)

5/ 50 (10)

14/ 50 (28)

20/ 50 (40)

9/ 49 (18.4)

23/ 50 (46)

18/48 (37.5)

20/ 50 (40)

17/ 50 (34)

NAT2*5/*5

0/ 50 (0)

0/ 50 (0)

3/ 49 (6.1)

0/ 50 (0)

1/ 48 (2.1)

0/ 50 (0)

0/ 50 (0)

NAT2*5/*6

4/ 50 (8)

0/ 50 (0)

3/ 49 (12.2)

3/ 50 (6)

3/ 48 (6.3)

1/ 50 (2)

2/ 50 (4)

NAT2*5/*7

3/ 50 (6)

0/ 50 (0)

18/ 49 (36.7)

0/ 50 (0)

4/ 48 (8.3)

0/ 50 (0)

3/ 50 (6)

NAT2*6/*6

8/ 50 (16)

2/ 50 (4)

0/ 49 (0)

4/ 50 (8)

2/ 48 (4.2)

4/ 50 (8)

3/ 50 (6)

NAT2*6/*7

7/ 50 (14)

6/ 50 (12)

6/ 49 ( 12.2)

9/ 50 (18)

6/ 48 (12.5)

3/ 50 (6)

8/ 50 (16)

NAT2*7/*7

6/ 50 (12)

16/ 50 (32)

7/ 49 (14.3)

1/ 50 (2)

5/ 48 (10.4)

8/ 50 (16)

3/ 50 (6)

Total

28/ 50 (56)

24/ 50 (48)

37/ 49 (75.5)

17/ 50 (36)

21/48 (43.8)

16/ 50 (32)

19/50 (38)

Total

NAT2 slow acetylator

The difference in three genotype categories (rapid, intermediate, and slow) among each of 7 Taiwanese ethnic populations was statistically
significant by Chi-square test (Chi-square = 32.08, p<0.05)

DISCUSSION
The Taiwanese mountain aboriginal tribes have
preserved their culture and languages because of
geographical isolation. Paiwan is the southernmost tribe
of Taiwan. The Atayal, Tsou, and Ami tribes are from the
northern and central parts of Taiwan, respectively. The
Yami tribe is on Orchid Island, which is 49 miles from
Taiwan. In addition, the HLA genotyping among different tribes showed high homogeneity and heterogeneity
in intra-tribes and inter-tribes, respectively, because of
low levels of admixture (22). Therefore, genetic polymorphisms of the drug metabolizing enzyme, NAT2, was
analyzed to elucidate drug metabolizing enzyme genetic
variation among Taiwan’s aboriginal and general groups.
In general, the percentages of NAT2 slow acetylator
were above 30% in the investigated aboriginal and general populations, which are different from the frequencies of 16.6-24.1% and 6.1% in Taiwanese and Japanese,
respectively, in the previous reports (12,13,18,19). In addition, the distribution of the NAT2 genotype in Paiwan
tribe revealed the highest proportion (75.5%) of slow
acetylators in our study, even higher than the propor-

tion in Caucasian, 55%(14,15). The allelic prevalence of
NAT2*5 and NAT2*7 in Paiwan and Atayal tribes was
not close to general people (Hakka and Minna) compared
to other aboriginal tribes (Table 1). It can be partially
explained by the relationships of the Taiwanese aboriginal and general populations which have been investigated
by neighbor-joining tree and principle components analysis(26,27). Paiwan, the southernmost population, clearly
differentiated from other aboriginal and general populations (27). However, other possible explanations may
remain as to the difference of allelic distribution among
populations.
Our data showed significant difference in the NAT2
genotypes within each of 7 Taiwanese ethnic populations
(Table 2), which may cause problem in the appropriate
dosing of specific medications, such as the anti-tuberculosis antibiotic, isoniazid (9). The increased incidence and
drug-resistance of tuberculosis has become an important
infectious disease control issue in Taiwan(29), especially
in the aboriginal mountain areas (30). In addition, it has
been reported that 83.3%, 2.3%, and 0% of isoniazidinduced, nausea/vomiting, fever, visual impairment, and
peripheral neuritis is observed in slow acetylators, inter-
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mediate acetylators, and rapid acetylators, respectively,
by Hiratsuka M., et al.(9). Isoniazid-induced hepatotoxicity was also found to a greater extent in slow acetylators as compared to rapid acetylators (26.4% vs. 11.1%)
in the Taiwanese general population (4). Therefore, our
results demonstrated the existence of drug-metabolizing
enzyme NAT2 genetic variation among aboriginal and
general populations, which may contribute to the medication induced adverse drug reactions in some populations.
To reach the goal of individualized medicine, many
studies have been focused on drug-metabolizing enzyme
genetic variations among races or ethnicities (31,32). Especially, information gleaned from SNP analysis provides
an important basis for individualized medicine. NAT2 is
one of the drug-metabolizing enzymes and its SNPs exert
a remarkable effect on drug-metabolism. According to
our findings, the therapeutic response and toxicity of
isoniazid may vary significantly among Taiwan’s ethnic
groups, especially in the Paiwan tribe, which consists of
a high percentage of slow acetylators. Further pharmacoepidemiology studies of isoniazid will be conducted to
elucidate the clinical importance of NAT2 genetic variations. In addition, SNPs analysis of other drug-metabolizing enzymes, such as cytochrome P450 2C9, 2C19,
and 2D6, will be performed in our populations to explore
important considerations for individualized medicine.
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